Navigation Links
OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
Date:4/22/2008

PORTLAND, Ore. An Oregon Health & Science University Cancer Institute researcher has identified a protein that is a strong indicator of survival for men with advanced prostate cancer. The C-reactive protein, also known as CRP, is a special type of protein produced by the liver that is elevated in the presence of inflammation.

"This could mean that a simple blood test that is already available could help in clinical decision making and patient counseling. Patients and doctors would know better what to expect from the prostate cancer they are facing," said Tomasz Beer, M.D., director of the Prostate Cancer Research Program at the OHSU Cancer Institute, associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.

Beer's research will be published online in the journal Cancer on Monday, April 21.

Past research has shown that cancer causes an inflammatory response. This research also suggests that inflammation may play an important role in driving prostate cancer progression and resistance to therapy. Inflammatory cells are attracted to cancer sites and this local inflammation can lead to a release of inflammatory markers, like CRP.

"While inflammation may sometimes slow the progression of the cancer, an increasing body of evidence suggests that cancer can actually take advantage of the inflammatory response, and the reaction of the immune system may fuel cancer progression. To the extent that our hypothesis proves true, C-reactive protein may be reflecting the overall intensity of the inflammation," Beer said.

The finding that higher CRP is associated with shorter survival and a lower probability of response to chemotherapy is a result of a secondary analysis of inflammatory markers in patients enrolled in the ASCENT study, a large Phase 2 clinical trial that evaluated treatment with docetaxel and DN-101, a high dose formulation of calcitriol or docetaxel with placebo. This analysis included patients from both groups. The analyses were supported by Novacea Inc., the sponsor of the ASCENT study. This new finding was in collaboration with Novacea.

Because this is the first time CRP has been linked with both response and survival in study subjects with advanced prostate cancer receiving chemotherapy, it will be important to confirm this finding in an independent data set before this can become a routine blood test for men with advanced prostate cancer, Beer explained.

If confirmed, besides providing useful information for the patient, this finding could also provide us with vital insight into the fundamental role of inflammation in the progression of advanced prostate cancer. A better understanding of this process could provide us with novel therapeutic interventions for control of this disease and its symptoms, Beer said.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Phone counseling improves quality of life, immune systems of cervical cancer survivors
2. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
3. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
4. Potential viral therapy weapon for difficult cancers is safe and effective in study
5. American Cancer Society report details cancer prevention efforts
6. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
7. Cancer cells spread by releasing bubbles, according to an MUHC study
8. Thousands of volunteers needed to help bring cure for cancer closer
9. Many Cancer Survivors Are Overweight and Sedentary: Study
10. Study reveals inaccuracies in studies of cancer treatment
11. Cancer survivors have low levels of physical activity and high levels of obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body ... with its product now available through Jet.com. , After 25 years of development, ... drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery ... Diane Winters. Diane is from Southwest Nebraska where she was raised on a ... family. The story is fictional, but the friendships and mantra of ‘neighbors helping ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... marketers of high-quality anti-aging skincare solutions, recently announced the launch of ... products are an affordable, yet effective alternative to expensive plastic surgery or in-patient ...
(Date:8/18/2017)... ... 2017 , ... “Case #10-5411 Veterans Administration”: a personal account ... #10-5411 Veterans Administration” is the creation of published author, Carol Mulhern, single mother ... Mulhem started work at the Coatesville VAMC as a file clerk then later ...
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait ... nurse, she took with her a dream to make nursing education more relevant and ... ensuring communication skills were integrated into healthcare provider education. , “The human ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/28/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced ... 30, 2017, and updated its financial outlook for fiscal ... the fiscal third quarter, Hill-Rom reported earnings of $0.09 ... in the prior-year period. These results reflect after-tax special ... primarily related to the non-cash write-down of assets associated ...
Breaking Medicine Technology: